Systemic Lupus Erythematosus

Bristol Myers Squibb announced positive results from a phase 2 trial that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.

Bristol Myers Squibb shares positive phase 2 results evaluating deucravacitinib in patients with moderate-to-severe systemic lupus erythematosus.

After years of frustration and failure, trials of targeted biologic therapy in systemic lupus erythematosus are beginning to show success. New drugs, including anifrolumab (Saphnelo) and belimumab (Benlysta), are paving the way for an exciting new era. However, this raises new questions as to how these novel therapeutics will be incorporated into future clinical practice.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 7, 2022.

The cross-sectional analysis determined cognitive performance of patients with systemic lupus erythematosus was significantly lower when compared with controls in both motor speed and psychomotor speed domains.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 30, 2022.

Manuel Francisco Ugarte-Gil, MD, MSc, explains the impact that severe flares have on health-related quality of life for patients with systemic lupus erythematosus.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 23, 2022.

Shanthini Kasturi, MD, MS, discusses the importance of patient-reported outcome measures to optimize the care of patients with systemic lupus erythematosus.

Joyce C. Chang MD, MSCE, discusses the racial disparities in renal outcomes for hospitalized children with systemic lupus erythematosus.

Until now, there has been limited information on the long-term safety and efficacy of belimumab in Chinese patients with systemic lupus erythematosus.

Disease flares in systemic lupus erythematosus are associated with damage. However, the impact of flares on health-related quality of life have not been analyzed.

Findings provide an advanced look at the potential future role of obinutuzumab in the management of SLE.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 26, 2021.

Iberdomide, a high-affinity cereblon modulator, works by affecting leukocyte development and autoimmunity.

New data support the continued assessment of the investigative drug for adults with SLE.

The rationale for using a newer monoclonal antibody therapy, anifrolumab, to manage patients with systemic lupus erythematosus.

Indications for belimumab, a monoclonal antibody, as therapy for patients with systemic lupus erythematosus.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 12, 2021.

More than 50% of patients with classified SLE at Washington University’s Lupus Clinic exhibit clinically meaningful and persistent depression and anxiety symptoms over time.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 5, 2021.

"For many years we lacked access to novel therapeutics in SLE and our outcomes frequently reflected this," stated Jack Arnold, MBBS, MRCP. "However, with new targeted therapies, we appear to be entering a new era where treatment decisions will require more nuanced thought."

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 18, 2021.

Roy Fleishmann, MD, discusses his Rheumatology Winter Clinical Symposium presentation, “SLE Update: Novel treatments, and how we assess them.”

Chengappa Kavadichanda, MD, discusses his study, “Short term outcomes of COVID-19 in lupus: Propensity score matched analysis from a nationwide multi-centric research network.”